4.72
Atyr Pharma Inc stock is traded at $4.72, with a volume of 5.05M.
It is down -4.45% in the last 24 hours and down -6.90% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$4.94
Open:
$4.9
24h Volume:
5.05M
Relative Volume:
1.55
Market Cap:
$420.10M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-15.03%
1M Performance:
-6.90%
6M Performance:
+22.28%
1Y Performance:
+138.38%
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ATYR
Atyr Pharma Inc
|
4.72 | 439.68M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-18-25 | Initiated | Leerink Partners | Outperform |
Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
Oct-04-24 | Initiated | Wells Fargo | Overweight |
Sep-05-24 | Initiated | Jefferies | Buy |
Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
Sep-21-21 | Initiated | Piper Sandler | Overweight |
May-10-21 | Initiated | Laidlaw | Buy |
Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Mar-04-20 | Initiated | ROTH Capital | Buy |
Mar-02-20 | Initiated | Oppenheimer | Outperform |
Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
Sep-07-17 | Initiated | Piper Jaffray | Overweight |
Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-16-15 | Initiated | Citigroup | Neutral |
Jun-01-15 | Initiated | Citigroup | Buy |
Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here? - Yahoo Finance
Price Channel Expanding on aTyr Pharma Inc.’s ChartReal Time Stock Movement Analysis Indicates Breakout - metal.it
Price Consolidation Hints at Upcoming Move in aTyr Pharma Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Wyckoff Accumulation Phase Possible in aTyr Pharma Inc.Entry Plan for Oversold Reversal Stocks Released - metal.it
Will aTyr Pharma Inc. Recover After Recent DeclineMarket Momentum Signal Generator Shows Trends - metal.it
aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks
What makes aTyr Pharma Inc. stock price move sharplyTrend Analysis for Safer Trades Gains Popularity - metal.it
aTyr Pharma Stock Faces Market Scrutiny Amid Financial Challenges - StocksToTrade
aTyr Pharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Entry and Exit Point Tips From Traders - metal.it
Is it the right time to buy aTyr Pharma Inc. stockAchieve breakthrough gains with smart trades - jammulinksnews.com
What are the technical indicators suggesting about aTyr Pharma Inc.Free Consultation - jammulinksnews.com
How does aTyr Pharma Inc. generate profit in a changing economyFree Stock Recommendation For Fast Growth - jammulinksnews.com
What are aTyr Pharma Inc. company’s key revenue driversGet daily updates on the hottest stocks - jammulinksnews.com
What is aTyr Pharma Inc. company’s growth strategyBuild a portfolio with strong long-term growth - jammulinksnews.com
How volatile is aTyr Pharma Inc. stock compared to the marketUnstoppable trading performance - jammulinksnews.com
Is aTyr Pharma Inc. a good long term investmentUnprecedented market success - PrintWeekIndia
Does aTyr Pharma Inc. stock pay reliable dividendsHigh-performance investment picks - jammulinksnews.com
RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP TherapeuticsResearchAndMarkets.com - FinancialContent
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga
aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest
aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout - TipRanks
What analysts say about aTyr Pharma Inc. stockMarket-leading capital gains - Autocar Professional
aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire
What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com
aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com
aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study - TipRanks
First-Ever Global Phase 3 Trial for Sarcoidosis Treatment Reaches Major Milestone with 268 Patients - Stock Titan
aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):